Iran is already seeing benefits of the nuclear agreement finalized on Tuesday.
The Tehran Stock Exchange rose 0.3%, with Tamin Petroleum & Petrochemical Investment Co. taking the highest gains at 3.2%. Two more oil and gas companies took 4.3% and 1.9% individual gains.
The country’s economy felt a bump as trading volume blossomed. About $136 million worth of shares traded for a 40% rise over Monday’s number. Iran’s currency slipped 0.1% to 29,500 per $1.
All of this was driven by the prospect of Iranian oil joining the global market again.
So too was the sudden drop in oil prices. On Tuesday morning, Brent Crude oil stood at just over $57 per barrel, but it quickly rebounded to $58.36 later that day. This came from an initial worry about Iran’s oil adding to the glut, followed by the realization that it would take some time — at least till the end of this year — to see some effect on the market.
And at what cost did Iran see this rise in numbers?
10 years of restricted nuclear development, the cutting of 98% of their over-enriched uranium inventory, and the stopper of two-thirds of its uranium centrifuges. So long as these conditions are met, both the U.S. and the E.U. will end sanctions and embargoes that have held back the Iranian economy for years.
Vicariously, the Gulf Cooperation Council’s numbers climbed too, lead by Oman, who had the strongest ties to Iran during the sanctions.
To continue reading…
Until next time,
A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.
For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.
Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.